Kairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors

Reuters

2025/10/16

<a href="https://laohu8.com/S/KAPA">Kairos Pharma</a> Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors

Kairos Pharma Ltd. has approved new compensation terms for its executive officers and directors, including the grant of $950,000 in restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan. The RSUs are based on the closing share price of $1.31 as of October 8, 2025, and will fully vest on October 8, 2026, provided the recipient remains with the company. In the event of a change in control before the vesting date, all unvested RSUs will immediately vest. Additionally, executive officers received cash bonuses for fiscal year 2024: Dr. Yu received $87,500, Dr. Bhomick $50,000, Dr. Murali $40,000, and Mr. Samuelson $50,000, totaling $227,500 in bonuses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018145), on October 15, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2575229756"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575229756\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575229756?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-16 04:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575229756","market":"fut","top_or_hot":-1,"title":"Kairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KAPA\">Kairos Pharma</a> Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kairos Pharma Ltd. has approved new compensation terms for its executive officers and directors, including the grant of $950,000 in restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan. The RSUs are based on the closing share price of $1.31 as of October 8, 2025, and will fully vest on October 8, 2026, provided the recipient remains with the company. In the event of a change in control before the vesting date, all unvested RSUs will immediately vest. Additionally, executive officers received cash bonuses for fiscal year 2024: Dr. Yu received $87,500, Dr. Bhomick $50,000, Dr. Murali $40,000, and Mr. Samuelson $50,000, totaling $227,500 in bonuses.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018145), on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-16 04:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KAPA\">Kairos Pharma</a> Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Kairos Pharma Ltd. has approved new compensation terms for its executive officers and directors, including the grant of $950,000 in restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan. The RSUs are based on the closing share price of $1.31 as of October 8, 2025, and will fully vest on October 8, 2026, provided the recipient remains with the company. In the event of a change in control before the vesting date, all unvested RSUs will immediately vest. Additionally, executive officers received cash bonuses for fiscal year 2024: Dr. Yu received $87,500, Dr. Bhomick $50,000, Dr. Murali $40,000, and Mr. Samuelson $50,000, totaling $227,500 in bonuses.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018145), on October 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nNDL96f3s8:1","article_id":"2575229756","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575229756","pubTimestamp":1760559083,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kairos Pharma Ltd. has approved new compensation terms for its executive officers and directors, including the grant of $950,000 in restricted stock units  under the company's 2023 Equity Incentive Plan. The RSUs are based on the closing share price of $1.31 as of October 8, 2025, and will fully vest on October 8, 2026, provided the recipient remains with the company. In the event of a change in control before the vesting date, all unvested RSUs will immediately vest. Additionally, executive officers received cash bonuses for fiscal year 2024: Dr. Yu received $87,500, Dr. Bhomick $50,000, Dr. Murali $40,000, and Mr. Samuelson $50,000, totaling $227,500 in bonuses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. publis","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KAPA":"Kairos Pharma, Ltd."},"translate_title":"Kairos Pharma宣布为高管和董事提供950,000美元的限制性股票单位和227,500美元的现金奖金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KAPA":0.9},"content_text":"Kairos Pharma Announces $950,000 in RSUs and $227,500 in Cash Bonuses for Executives and Directors\n    \n\n        Kairos Pharma Ltd. has approved new compensation terms for its executive officers and directors, including the grant of $950,000 in restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan. The RSUs are based on the closing share price of $1.31 as of October 8, 2025, and will fully vest on October 8, 2026, provided the recipient remains with the company. In the event of a change in control before the vesting date, all unvested RSUs will immediately vest. Additionally, executive officers received cash bonuses for fiscal year 2024: Dr. Yu received $87,500, Dr. Bhomick $50,000, Dr. Murali $40,000, and Mr. Samuelson $50,000, totaling $227,500 in bonuses.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018145), on October 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}